Showing 6 of 46 recruiting trials for “splenic-marginal-zone-lymphoma”
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
👨⚕️ Marco Ladetto, S.C. Ematologia - A.S.O. "SS Antonio e Biagio e Cesare Arrigo" di Alessandria📍 21 sites📅 Started Mar 2022View details ↗
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
👨⚕️ Stephen D Smith, Academic and Community Cancer Research United📍 7 sites📅 Started Aug 2021View details ↗
Avo In R/R And Previously Untreated MCL
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
👨⚕️ Martin Dreyling, Prof., Klinikum der Universität München📍 112 sites📅 Started Jul 2016View details ↗
← PreviousPage 3 of 3
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →